| Literature DB >> 23283538 |
Ryo Rokutanda1, Mitsumasa Kishimoto, Sachiko Ohde, Hisanori Shimizu, Atsushi Nomura, Yasuhiro Suyama, Yuri Ohara, Kenichi Yamaguchi, Masato Okada.
Abstract
The objective of this study was to examine the safety and efficacy of mizoribine (MZR), an inhibitor of inosine monophosphate dehydrogenase, in patients with connective tissue diseases (CTDs) other than rheumatoid arthritis. We identified all patients who had ever been treated with MZR for CTDs at our institution during the period from January 2001 to May 2011. A retrospective review of medical records was performed to evaluate safety and efficacy of MZR. A total of 63 patients (13 induction and 50 maintenance therapy with MZR) were included. During 70.2 patient-years of follow-up, only one patient required discontinuation of MZR due to an adverse event. Doses of PSL were significantly decreased at last follow-up in both the induction (45.2 ± 15.6 vs. 8.4 ± 5.7 mg/day, p < 0.01) and the maintenance group (12.4 ± 7.6 vs. 9.3 ± 6.4 mg/day, p < 0.01). MZR appears to be a safe and well-tolerated steroid-sparing agent in patients with CTDs.Entities:
Mesh：
Substances：
Year: 2013 PMID： 23283538 DOI： 10.1007/s00296-012-2633-8
Source DB: PubMed Journal: Rheumatol Int ISSN： 0172-8172 Impact factor: 2.631